Supplementary Appendices Appendix 1 Figure S1 Incidence of Type 2 Diabetes Mellitus... 2 Appendix 2 Figure S2 Percentage prevalence of Type 2
|
|
|
- Jeremy Shaw
- 5 years ago
- Views:
Transcription
1 Supplementary Appendices Appendix 1 Figure S1 Incidence of Type 2 Diabetes Mellitus... 2 Appendix 2 Figure S2 Percentage prevalence of Type 2 Diabetes Mellitus... 3 Appendix 3 - Table S1 Prevalence of prescribing of different anti-diabetic classes among all Type 2 diabetics on medication... 4 Appendix 4 - Table S2 Prevalence of prescribing of different anti-diabetic classes used to initiate treatment in newly diagnosed Type 2 diabetics Appendix 5 - Table S3 Prevalence of prescribing of different anti-diabetic classes used as add-on agents in Type 2 Diabetics on metformin Appendix 6 - Table S4 Prevalence of prescribing of different anti-diabetic classes used as add-on agents in Type 2 Diabetics on sulphonylureas
2 Appendix 1 Figure S1 Incidence of Type 2 Diabetes Mellitus Male Female
3 Prevalence(%) Appendix 2 Figure S2 Percentage prevalence of Type 2 Diabetes Mellitus
4 Appendix 3 - Table S1 Prevalence of prescribing of different anti-diabetic classes among all Type 2 diabetics on medication N=Total number of Type 2 diabetics in a calendar year prescribed any anti-diabetic medicines; Metf=metformin; Sulf=sulphonylurea; Ins=Insulins; Glipt=gliptins; Thiazol=thiazolidinediones; GLP-1=glucagon-like-peptide-1 analogues; Megl-meglitinides; Acar=acarbose; SGLT=sodium-glucose co-transporter2 inhibitors Year N Metf%(95%CI) Sulf%(95%CI) Ins%(95%CI) Glipt%(95%CI) Thiazol%(95%CI) GLP-1%(95%CI) Megl%(95%CI) Acar%(95%CI) SGLT%(95%CI) , (55.0 to 55.8) 64.8 (64.3 to 65.2) 20.4 (20.0 to 20.7) (1.1 to 1.3) (0.8 to 1.0) 4.2 (4.0 to 4.4) , (59.1 to 59.9) 61.2 (60.8 to 61.6) 21.4 (21.0 to 21.7) (5.2 to 5.6) (1.1 to 1.3) 3.3 (3.1 to 3.4) , (63.5 to 64.2) 56.7 (56.3 to 57.1) 21.7 (21.4 to 22.1) (7.6 to 8.0) (1.6 to 1.8) 2.7 (2.5 to 2.8) , (67.4 to 68.1) 53.0 (52.6 to 53.4) 22.6 (22.3 to 22.9) (10.3 to 10.8) (1.5 to 1.7) 2.2 (2.1 to 2.3) , (71.0 to 71.6) 49.5 (49.2 to 49.9) 23.4 (23.1 to 23.7) (12.8 to 13.3) (1.3 to 1.5) 1.8 (1.7 to 1.9) , (73.1 to 73.7) 47.0 (46.6 to 47.3) 23.7 (23.4 to 24.0) (14.6 to 15.1) (1.1 to 1.2) 1.5 (1.4 to 1.5) , (74.0 to 74.6) 45.1 (44.7 to 45.4) 23.7 (23.4 to 23.9) (15.7 to 16.2) (0.8 to 1.0) 1.2 (1.1 to 1.3) , (74.8 to 75.3) 43.9 (43.6 to 44.2) 23.5 (23.2 to 23.8) 0.2 (0.2 to 0.2) 16.0 (15.8 to 16.3) 0.1 (0.1 to 0.2) 0.9 (0.8 to 0.9) 1.0 (0.9 to 1.0) , (76.9 to 77.4) 43.8 (43.5 to 44.1) 23.5 (23.3 to 23.8) 1.2 (1.1 to 1.2) 14.7 (14.4 to 14.9) 0.8 (0.8 to 0.9) 0.9 (0.8 to 0.9) 0.8 (0.7 to 0.9) , (78.8 to 79.3) 43.7 (43.4 to 44.1) 23.3 (23.0 to 23.6) 3.6 (3.5 to 3.7) 13.9 (13.7 to 14.1) 2.0 (1.9 to 2.1) 0.8 (0.7 to 0.8) 0.7 (0.6 to 0.7) , (81.2 to 81.7) 43.4 (43.1 to 43.7) 22.8 (22.6 to 23.1) 7.6 (7.5 to 7.8) 13.6 (13.4 to 13.8) 3.4 (3.3 to 3.5) 0.7 (0.6 to 0.7) 0.6 (0.5 to 0.6) , (82.3 to 82.8) 42.8 (42.5 to 43.1) 22.8 (22.5 to 23.1) 10.5 (10.3 to 10.7) 11.7 (11.5 to 11.9) 4.3 (4.2 to 4.4) 0.6 (0.5 to 0.6) 0.5 (0.4 to 0.5) , (82.8 to 83.3) 42.3 (41.9 to 42.6) 23.1 (22.8 to 23.3) 13.4 (13.2 to 13.6) 9.9 (9.7 to 10.1) 5.0 (4.8 to 5.1) 0.5 (0.5 to 0.5) 0.4 (0.4 to 0.5) , (83.4 to 83.8) 41.4 (41.1 to 41.7) 23.3 (23.0 to 23.6) 15.4 (15.2 to 15.7) 8.5 (8.3 to 8.7) 5.3 (5.2 to 5.5) 0.5 (0.4 to 0.5) 0.4 (0.3 to 0.4) 0.5 (0.5 to 0.6) 4
5 Appendix 4 - Table S2 Prevalence of prescribing of different anti-diabetic classes used to initiate treatment in newly diagnosed Type 2 diabetics. N= Total number of newly diagnosed Type 2 diabetics in a calendar year initiated on anti-diabetic medicines; Metf=metformin; Sulf=sulphonylurea; Ins=Insulins; Glipt=gliptins; Thiazol=thiazolidinediones; GLP-1=glucagon-like-peptide-1 analogues; Megl-meglitinides; Acar=acarbose; SGLT=sodium-glucose co-transporter2 inhibitors Year N Metf%(95%CI) Sulf%(95%CI) Ins%(95%CI) Glipt%(95%CI) Thiazol%(95%CI) GLP-1%(95%CI) Megl%(95%CI) Acar%(95%CI) SGLT%(95%CI) , (43.2 to 47.1) 51.1 (49.2 to 53.0) 3.1 (2.4 to 3.7) (0.3 to 0.8) 0.2 (0 to 0.3) , (55.1 to 58.0) 40.0 (38.6 to 41.5) 2.8 (2.3 to 3.3) (0 to 0.2) (0.1 to 0.4) 0.2 (0.1 to 0.3) , (65.1 to 67.5) 29.8 (28.6 to 31.0) 2.9 (2.5 to 3.4) (0.3 to 0.6) (0.2 to 0.6) 0.1 (0 to 0.2) , (73.5 to 75.5) 21.6 (20.7 to 22.6) 2.9 (2.5 to 3.3) (0.4 to 0.8) (0.1 to 0.3) 0.2 (0.1 to 0.3) , (78.6 to 80.3) 16.4 (15.6 to 17.1) 2.7 (2.3 to 3.0) (0.9 to 1.3) (0.1 to 0.3) 0.2 (0.1 to 0.3) , (81.3 to 82.9) 14.1 (13.4 to 14.8) 2.4 (2.1 to 2.7) (0.9 to 1.3) (0 to 0.2) 0.1 (0.1 to 0.2) , (83.7 to 85.1) 12.0 (11.4 to 12.7) 2.5 (2.2 to 2.9) (0.7 to 1.1) (0 to 0.1) 0.2 (0.1 to 0.2) , (86.2 to 87.5) 10.2 (9.6 to 10.7) 2.3 (2.0 to 2.6) (0.4 to 0.6) (0 to 0.2) 0.1 (0 to 0.1) , (86.9 to 88.1) 9.7 (9.2 to 10.3) 2.4 (2.1 to 2.6) (0.1 to 0.3) (0 to 0.1) 0.1 (0 to 0.1) , (88.6 to 89.7) 8.7 (8.2 to 9.2) 1.8 (1.5 to 2.0) 0.1 (0.1 to 0.2) 0.1 (0.1 to 0.2) 0.1 (0 to 0.1) 0.1 (0 to 0.1) , (89.3 to 90.4) 7.8 (7.3 to 8.2) 1.9 (1.6 to 2.1) 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.2) 0.1 (0 to 0.1) , (89.6 to 90.7) 7.7 (7.2 to 8.2) 1.7 (1.5 to 1.9) 0.3 (0.2 to 0.4) 0.1 (0.0 to 0.1) 0.1 (0 to 0.1) , (89.9 to 90.9) 7.4 (6.9 to 7.9) 1.5 (1.2 to 1.7) 0.5 (0.4 to 0.7) (0 to 0.1) (0 to 0.1) , (90.5 to 91.5) 6.3 (5.9 to 6.8) 1.7 (1.4 to 1.9) 0.8 (0.7 to 1.0) 0.1 (0. to 0.1)
6 Appendix 5 - Table S3 Prevalence of prescribing of different anti-diabetic classes used as add-on agents in Type 2 Diabetics on metformin. N= Total number of newly diagnosed Type 2 diabetics in a calendar year initiated on metformin who were subsequently prescribed add-on therapy; Sulf=sulphonylurea; Ins=Insulins; Glipt=gliptins; Thiazol=thiazolidinediones; GLP-1=glucagon-like-peptide-1 analogues; Megl-meglitinides; Acar=acarbose; SGLT=sodium-glucose cotransporter2 inhibitors Year N Sulf%(95%CI) Ins%(95%CI) Glipt%(95%CI) Thiazol%(95%CI) GLP-1%(95%CI) Megl%(95%CI) Acar%(95%CI) SGLT%(95%CI) (72.6 to 79.3) 0.8 (0.1 to 1.5) 1.3 (0.4 to 2.1) 18.8 (15.7 to 21.8) (1.1 to 3.3) 1.1 (0.3 to 1.9) , (66.2 to 71.1) 1.4 (0.8 to 2.0) 2.0 (1.2 to 2.7) 24.0 (21.7 to 26.3) 0.2 (0 to 0.5) 3.2 (2.2 to 4.1) 0.6 (0.2 to 1) , (64.0 to 68.1) 1.3 (0.8 to 1.8) 2.5 (1.8 to 3.1) 26.9 (25.0 to 28.8) 0.3 (0.1 to 0.6) 2.4 (1.8 to 3.1) 0.5 (0.2 to 0.8) , (64.9 to 68.5) 1.7 (1.2 to 2.2) 3.9 (3.2 to 4.7) 26.5 (24.8 to 28.2) 0.3 (0.1 to 0.6) 0.8 (0.5 to 1.1) 0.1 (0 to 0.2) , (66.0 to 69.2) 1.9 (1.5 to 2.4) 4.9 (4.1 to 5.6) 24.2 (22.7 to 25.7) 0.5 (0.2 to 0.7) 0.6 (0.3 to 0.8) 0.1 (0 to 0.2) 0.2 (0.1 to 0.4) , (66.6 to 69.7) 1.7 (1.3 to 2.2) 7.4 (6.6 to 8.3) 21.6 (20.2 to 23.0) 0.5 (0.3 to 0.8) 0.5 (0.3 to 0.7) (0 to 0.1) , (66.6 to 69.7) 1.8 (1.4 to 2.3) 10.5 (9.5 to 11.5) 18.1 (16.9 to 19.4) 0.8 (0.5 to 1.1) 0.4 (0.2 to 0.6) 0.1 (0 to 0.2) 0 (0 to 0.1) , (71.1 to 73.9) 2.3 (1.8 to 2.8) 13.0 (12.0 to 14.1) 10.5 (9.6 to 11.5) 1.0 (0.7 to 1.3) 0.5 (0.2 to 0.7) 0.1 (0 to 0.2) 0.1 (0 to 0.2) , (67.8 to 70.7) 2.0 (1.6 to 2.5) 17.2 (16.1 to 18.4) 9.4 (8.5 to 10.3) 1.4 (1.0 to 1.7) 0.4 (0.2 to 0.6) (0.1 to 0.3) , (64.9 to 67.9) 2.4 (1.9 to 2.9) 22.8 (21.5 to 24.2) 6.1 (5.4 to 6.9) 1.5 (1.1 to 1.9) 0.3 (0.1 to 0.4) 0.1 (0 to 0.2) 0.3 (0.2 to 0.5) , (62.4 to 65.7) 2.3 (1.8 to 2.8) 25.5 (24.0 to 27.0) 4.9 (4.2 to 5.7) 2.1 (1.6 to 2.6) 0.3 (0.1 to 0.5) (0.5 to 1.1) , (62.7 to 66.4) 3.7 (3.0 to 4.5) 25.6 (23.9 to 27.2) 3.1 (2.4 to 3.7) 1.8 (1.3 to 2.4) 0.2 (0 to 0.4) - 1.0(0.6 to 1.4) , (61.9 to 65.9) 4.1 (3.2 to 4.9) 26.2 (24.3 to 28.1) 2.2 (1.6 to 2.8) 1.8 (1.3 to 2.4) 0.2 (0 to 0.4) 0.1 (0 to 0.2) 1.5 (1.0 to 2.0) , (59.2 to 64.2) 3.8 (2.8 to 4.8) 26.9 (24.7 to 29.2) 1.9 (1.2 to 2.7) 1.3 (0.7 to 1.9) 0.1 (0 to 0.3) 0.1 (0 to 0.2) 4.0 (3.0 to 5.0) 6
7 Appendix 6 - Table S4 Prevalence of prescribing of different anti-diabetic classes used as add-on agents in Type 2 Diabetics on sulphonylureas. N= Total number of newly diagnosed Type 2 diabetics in a calendar year initiated on sulphonylureas who were subsequently prescribed add-on therapy; Metf=metformin; Ins=Insulins; Glipt=gliptins; Thiazol=thiazolidinediones; GLP-1=glucagon-like-peptide-1 analogues; Megl-meglitinides; Acar=acarbose; SGLT=sodium-glucose cotransporter2 inhibitors. Year N Metf%(95%CI) Ins%(95%CI) Glipt%(95%CI) Thiazol%(95%CI) GLP-1%(95%CI) Megl%(95%CI) Acar%(95%CI) SGLT%(95%CI) (87.7 to 92.0) 3.7 (2.4 to 5.1) 0.4 (0 to 0.9) 5.5 (3.9 to 7.1) (0 to 0.6) 0.3 (0 to 0.6) (87.2 to 91.1) 5.0 (3.6 to 6.4) 0.6 (0.1 to 1.1) 4.4 (3.1 to 5.7) (0.1 to 1) 0.3 (0 to 0.7) (84.3 to 88.7) 4.8 (3.4 to 6.1) 0.2 (0 to 0.5) 7.9 (6.1 to 9.6) (0 to 0.9) 0.2 (0 to 0.5) (81.8 to 86.9) 6.9 (5.2 to 8.7) 0.3 (0 to 0.6) 7.9 (6.1 to 9.8) (0 to 0.8) 0.1 (0 to 0.4) (80.8 to 86.3) 7.7 (5.7 to 9.6) 0.9 (0.2 to 1.5) 7.7 (5.7 to 9.6) (0 to 0.4) 0.1 (0 to 0.4) (82.1 to 87.7) 7.1 (5.1 to 9.1) 1.1 (0.3 to 2.0) 6.3 (4.4 to 8.2) (0 to 1.3) (78.4 to 85.1) 10.4 (7.7 to 13.0) 2.3 (1.0 to 3.6) 4.8 (3.0 to 6.6) (0 to 1.2) 0.2 (0 to 0.6) (77.7 to 84.7) 10.6 (7.9 to 13.4) 2.7 (1.3 to 4.2) 5.0 (3.1 to 7.0) (0 to 1.0) (81.1 to 88.0) 6.9 (4.5 to 9.3) 3.3 (1.6 to 5.0) 4.3 (2.3 to 6.2) (0 to 1.5) 0.2 (0 to 0.7) (81.2 to 88.2) 9.9 (7.0 to 12.8) 3.2 (1.5 to 4.9) 2.0 (0.6 to 3.3) (0 to 0.7) (73.5 to 82.2) 11.9 (8.5 to 15.3) 8.8 (5.8 to 11.8) 1.4 (0.2 to 2.7) (78.6 to 86.9) 7.2 (4.4 to 10.1) 8.8 (5.7 to 11.9) 0.9 (0 to 2.0) 0.3 (0 to 0.9) (76.9 to 85.5) 11.5 (7.9 to 15.0) 5.1 (2.7 to 7.5) 2.2 (0.6 to 3.9) (74.8 to 85.0) 13.4 (9.1 to 17.7) 6.3 (3.2 to 9.4) 0.4 (0 to 1.2)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
MOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
2017 Hot topics in cardiometabolism: an interactive update
14-15 July, 2017 - Bogotà, Colombia 2017 Hot topics in cardiometabolism: an interactive update IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Nicola Napoli Department of Medicine,
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
Type Two Diabetes Mellitus Prescribing in New Zealand - What are we dispensing?
Type Two Diabetes Mellitus Prescribing in New Zealand - What are we dispensing? Dr Bryan Betty Deputy Medical Director PHARMAC GP Cannons Creek, East Porirua Type 2 Diabetes in NZ: The Numbers 250,000
Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and. Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice
Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice Authors: Chi-Chen Lin, Der-Yuan Chen, Ya-Hsuan Chao,
Cost Effectiveness of canagliflozin (Invokana )
Cost Effectiveness of canagliflozin (Invokana ) for adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on therapy with other anti-hyperglycaemic agents including insulin,
How can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
Scottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
SGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
Summary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin)
EMA/217413/2015 Summary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin) This is a summary of the risk management plan (RMP) for Synjardy, which details the measures to be taken
Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
Glucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
National Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
SGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
Diabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
INCRETIN THERAPY ROUNDTABLE: Putting recommendations into practice. Program guide
INCRETIN THERAPY ROUNDTABLE: Putting recommendations into practice Program guide 1 TABLE OF CONTENTS Objectives. 2 Case study and interactive questions... 3 Top 5 clinical tips..... 11 OBJECTIVES After
CADTH Optimal use report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal use report Volume 3, Issue 1D July 2013 Optimal Use Recommendations
Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
NEW SA DIABETES GUIDELINES
Earn 3 CPD Points online 2017 SEMDSA diabetes management guidelines The updated 2017 South African guidelines for the management of type 2 diabetes mellitus were launched on 5 May at the 52 nd congress
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
Optimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 September 2012 (Issued 07 December 2012) The Scottish Medicines Consortium (SMC) has completed
Scottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
Drug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
Management of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
Comments. Type 2 Diabetes
Stakeholder organisation(s) (or your name if you are commenting as an individual): Name of commentator (leave blank if you are commenting as an individual): Document Comment (full version, short version
Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
Supplementary Online Content
Supplementary Online Content Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of Noninsulin Antidiabetic Drugs Added to Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes.
TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period
Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period Dr Ketan Dhatariya MBBS MSc MD MS FRCP Consultant in Diabetes and Endocrinology Norfolk and Norwich
Correlates of second-line type 2 diabetes medication selection in the USA
Open Access To cite: Ackermann RT, Wallia A, O'Brien MJ, et al. Correlates of second-line type 2 diabetes medication selection in the USA. BMJ Open Diab Res Care 2017;5:e000421. doi:10.1136/ bmjdrc-2017-000421
MANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
Downloaded from:
Mamza, J; Mehta, R; Donnelly, R; Idris, I (2016) Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase- 4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
Efficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
INJECTABLE THERAPIES IN DIABETES. Barbara Ann McKee Diabetes Specialist Nurse
INJECTABLE THERAPIES IN DIABETES Barbara Ann McKee Diabetes Specialist Nurse 1 Aims of the session Describe the different injectable agents for diabetes and when they would be used. Describe some common
Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
Diabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10
6 Diabetes Care Volume 41, January 2018 PERSPECTIVES IN CARE Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 https://doi.org/10.2337/dc17-1223
Epidemiology and Multimorbidity of Type 2 Diabetes and the Risk of. Major Cardiovascular Events
Epidemiology and Multimorbidity of Type 2 Diabetes and the Risk of Major Cardiovascular Events A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
CADTH Optimal Use Report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal Use Report Volume 3, Issue 1B July 2013 Third-Line Pharmacotherapy for
Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
The first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
Sitagliptin. Agreed by Clinical Priorities Group
New Medicine Report Document Status Sitagliptin Agreed by Clinical Priorities Group Traffic Light Decision Blue- Primary Care Prescriber s Rating Offers an advantage - The product has some value but does
Drugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
Dr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
SMC briefing note. The following medicines were accepted for use: Contact details. About SMC. Media contact. Number 98 January 2016
Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medicines Consortium. The detailed advice for each medicine
Update on Pharmacological Management in Type 2 Diabetes
Update on Pharmacological Management in Type 2 Diabetes Prof. Lotfy Hamed Abo Dahab Professor Of Internal Medicine and Cardiology Vice President of Sohag University ١ My AGENDA Targets For Glycaemic Control
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) Bulletin Glucagon-like peptide 1 (GLP-1) receptor agonist review
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) February 2017 Review February 2020 Bulletin 245 - Glucagon-like peptide 1 (GLP-1) receptor agonist review JPC Recommendations:- Place in therapy
There have been important changes in diabetes care which may not be covered in undergraduate textbooks.
Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Navari RM, Qin R, Ruddy KJ, et al. for the prevention of chemotherapy-induced
Dr Karen McNeil Consultant Endocrinologist
Dr Karen McNeil Consultant Endocrinologist Aged 53 Type 2 Diabetes 2010 HbA1c 7.9% ACR 5.3 mg/mmol What treatment? MF 500 mg bd (misses midday dose) Control Symptoms, BGL Complications DR, DN, PN Associations
Bristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
Jeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October Your DM patient is ready for discharge, now what?
Jeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October 2018 Your DM patient is ready for discharge, now what? Financial Disclosures None Objectives 1. Understand follow up patterns/capability of patients
SYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
Drug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
WHO Guidelines for Management of Diabetes in Low Resource Settings
WHO Guidelines for Management of Diabetes in Low Resource Settings 24 th November, 2018 Dr. Alok Shetty K Senior Resident Department of Medicine St. John s Medical College & Hospital WHO vs ADA-EASD Revisiting
Supplementary Online Content
Supplementary Online Content Berkowitz SA, Krumme AA, Avorn J, et al. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA
National Institute for Health and Care Excellence. Type 2 diabetes. Stakeholder Comments Draft Guideline
National Institute for Health and Care Excellence Type 2 diabetes Stakeholder Comments Draft Guideline NOTE: NICE is unable to accept comments from non-registered organisations or individuals. If you wish
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
Patients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study
International Journal of Advances in Medicine Gadge PV et al. Int J Adv Med. 2018 Apr;5(2):424-428 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20181082
Chief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
UKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
Congestive Heart Failure: The Complication that Gets No Respect Richard J. Katz, MD Saturday, February 18, :30 a.m. 10:15 a.m.
Congestive Heart Failure: The Complication that Gets No Respect Richard J. Katz, MD Saturday, February 18, 2017 9:30 a.m. 10:15 a.m. The prevalence of the combination of diabetes and both systolic and
Name: Oasis: Questions EPCP. Professional Development: Diabetes
EPCP Professional Development: Diabetes Name: Oasis: Questions 1) Type 1 diabetes in characterized by which of the following: 1) adult onset, obesity 2) juvenile onset, lean build 3) auto-immune beta cell
Inpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
What s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
Combination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION
OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION Biljana Parapid, MD, PhD, FESC Belgrade University School of Medicine, Belgrade (Serbia) @biljana_parapid COI International
Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
What s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
Horizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
PLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:
Metformin Standard tablets Modified-release tablets Metformin 1g sachets Metformin liquid 500mg/5ml (avoid use as expensive) < 2.00 5.32 for 56 tabs 500mg 13.16 for 60 sachets > 120 Ketoacidosis General
A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide
A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly
ABSTRACT. peptidase-4 inhibitors, sodium-glucose cotransporter-2
Diabetes Ther (2018) 9:2133 2141 https://doi.org/10.1007/s13300-018-0483-4 BRIEF REPORT Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium- Glucose Co-Transporter-2
GUIDELINE FOR THE MANAGEMENT OF HYPOGLYCAEMIA IN ADULTS WITH DIABETES MELLITUS
GUIDELINE FOR THE MANAGEMENT OF HYPOGLYCAEMIA IN ADULTS WITH DIABETES MELLITUS Guideline author Accountable Executive Lead Approving body Policy reference Diabetes Specialist Nurse Consultant Diabetologist
SMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
The Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
Diabetes(Mellitus( Dr(Kawa(A.(Obeid( PhD!Therapeutics!
DiabetesMellitus DrKawaA.Obeid PhDTherapeutics 1 Definitionandabriefintroduction Diabetes mellitus is the most common of the endocrine disorders. It is primarily a disorder of carbohydratemetabolismcharacterisedbyhyperglycaemia,thisisduetoimpairedinsulinsecretion
What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations
Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee
Diabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.
Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the